江苏四环生物股份有限公司 2015 年第三季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2015-69 号 江苏四环生物股份有限公司 2015 年第三季度报告正文 1 江苏四环生物股份有限公司 2015 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员)徐殷声明：保证季度报告 中财务报表的真实、准确、完整。 2 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 855,442,572.59 | 818,082,450.17 | | 4.57% | | 归属于上市公司股东的净资产 | 676,442,658.31 | ...

Financial Performance - The company's operating revenue for the first half of 2015 was CNY 108,698,999.38, a decrease of 17.53% compared to the same period last year[21]. - The net profit attributable to shareholders was CNY 4,096,891.98, representing an 82.08% decline year-on-year[21]. - The net profit after deducting non-recurring gains and losses was CNY 1,103,798.61, down 94.47% from the previous year[21]. - The net cash flow from operating activities was negative CNY 167,421,356.08, a significant decrease of 2,337.80% compared to the same period last year[21]. - The weighted average return on net assets was 0.80%, down from 3.33% in the previous year[21]. - The basic earnings per share decreased to CNY 0.0040, an 81.98% decline compared to the same period last year[21]. - The company reported a net loss of CNY 2.87 million for the current period, reflecting a decrease of 124.53% compared to the previous period[48]. - The total comprehensive income for the period was CNY 2,246,052.38, down from CNY 21,245,316.18, reflecting overall financial challenges[116]. - The total comprehensive income for the current period was a loss of CNY 3,727,929.91, compared to a loss of CNY 1,997,139.83 in the previous period, reflecting a worsening of approximately 86.7%[119]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 847,892,510.68, an increase of 3.64% from the end of the previous year[21]. - The company's total current assets increased to CNY 396,775,684.81 from CNY 348,625,967.93, representing a growth of approximately 13.5%[105]. - Inventory surged significantly to CNY 164,285,173.78, up from CNY 42,344,781.99, indicating an increase of about 287.5%[105]. - Total liabilities rose to CNY 124,054,520.38 from CNY 96,490,512.25, reflecting an increase of approximately 28.7%[107]. - The company's total assets reached CNY 847,892,510.68, compared to CNY 818,082,450.17 at the beginning of the period, marking a growth of about 3.4%[108]. - The company's cash and cash equivalents decreased to CNY 18,149,713.44 from CNY 34,747,081.43, a decline of approximately 47.8%[105]. - Accounts receivable increased to CNY 100,827,120.39 from CNY 84,334,453.12, showing a rise of about 19.6%[105]. - The total liabilities rose to CNY 240,199,225.01, compared to CNY 75,159,115.65, indicating a substantial increase in financial obligations[112]. Investments and Projects - The company plans to invest in the Xinjiang Aidi New Energy project, but faces challenges due to declining international oil prices and funding shortages[29]. - The total planned investment for the Xinjiang Aidi factory and production facilities is CNY 451.98 million, with CNY 76.9 million invested in the current reporting period and a cumulative actual investment of CNY 85.968 million, representing 19.02% project progress[50]. - The company made an external investment of ¥90,000,000.00 during the reporting period, marking a significant increase from the previous year[38]. - The company has made investments in new product development and technology, focusing on coal chemical products and catalysts[48]. Shareholder Information - The total number of shares after the recent changes is 1,029,556,222, with 100% being unrestricted shares[88]. - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 40,000,000 shares, representing 3.89% of total shares[91]. - The second largest shareholder, Kunshan Chuangye Investment Co., Ltd., holds 31,785,868 shares, representing 3.09% of total shares[91]. - The total number of shareholders at the end of the reporting period is 178,062[90]. - There were no changes in the controlling shareholder or actual controller during the reporting period[93]. - The company did not distribute any dividends or profits to shareholders during this period[132]. Corporate Governance and Compliance - The company has not engaged in any asset acquisitions or sales during the reporting period[61][62]. - The company has not implemented any equity incentive plans during the reporting period[64]. - The company has not undergone any bankruptcy reorganization during the reporting period[60]. - The company has not reported any media controversies during the reporting period[59]. - The semi-annual financial report has not been audited[81]. - The company has experienced changes in its supervisory board, with new employee supervisors elected on June 12, 2015[100]. Accounting Policies - The company’s financial statements are prepared based on the going concern principle and comply with the relevant accounting standards[143]. - The company uses Renminbi as its functional currency for accounting[149]. - The company recognizes assets and liabilities acquired in business combinations at their book value on the merger date for same-control mergers[150]. - The company consolidates all subsidiaries under its control in its financial statements, reflecting the overall financial status and results of the group[154]. - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, with specific methods for different types of financial assets[172]. - The company applies a provision for bad debts based on aging, with a 5% provision for accounts receivable within 1 year and 100% for those over 5 years[175].

江苏四环生物股份有限公司 2015 年第一季度报告全文 江苏四环生物股份有限公司 2015 年第一季度报告 2015 年 04 月 1 江苏四环生物股份有限公司 2015 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐殷声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2015 年第一季度报告全文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业收入（元） | 46,987,464.09 | 74,755,076.02 | | -37.14% | | 归属于上市公司股东的净利润（元） | ...

Revenue and Profit - Revenue for Q1 2015 was CNY 46,987,464.09, a decrease of 37.14% compared to CNY 74,755,076.02 in the same period last year[8] - Net profit attributable to shareholders was CNY 10,098,042.27, down 21.31% from CNY 12,833,227.70 year-on-year[8] - Basic earnings per share decreased by 21.60% to CNY 0.0098 from CNY 0.0125 in the previous year[8] - Operating revenue decreased by 37.14% to ¥46,987,464.09, reflecting a sales decline in Beijing and Jiangsu[15] - Operating costs fell by 34.82% to ¥16,995,134.75, corresponding to the decrease in revenue[15] - Sales expenses dropped by 81.80% to ¥1,986,607.25, as advertising costs were reduced[15] Cash Flow and Assets - Net cash flow from operating activities improved significantly to CNY 740,056.43, a 225.15% increase from a negative CNY 591,346.92 in the same period last year[8] - Cash and cash equivalents increased by 94.05% to ¥67,425,552.42 due to new short-term borrowings[15] - Financing activities generated a net cash flow of ¥33,968,977.25, a significant increase due to new short-term borrowings[16] - Total assets at the end of the reporting period were CNY 848,931,843.93, reflecting a 3.77% increase from CNY 818,082,450.17 at the end of the previous year[8] - Net assets attributable to shareholders increased by 1.48% to CNY 691,165,638.75 from CNY 681,067,596.48 at the end of the previous year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 1,029,556,222[11] - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 3.89% of shares, amounting to 40,000,000 shares, with some shares pledged[11] - There were no share buyback transactions conducted by the top ten shareholders during the reporting period[12] Other Financial Activities - The company reported no significant non-recurring gains or losses during the reporting period[9] - The company has not made any new investments in intangible assets during the reporting period[15] - There are no securities investments or derivative investments reported for the period[21][20] - Accounts receivable interest rose by 818.18% to ¥2,160,277.78, attributed to interest from entrusted loans[15] Company Status - The company is currently in discussions regarding a major matter that has led to the suspension of its stock since March 6, 2015[17]

Financial Performance - The company's operating revenue for 2014 was CNY 241,230,724.74, representing a 15.56% increase compared to CNY 208,745,143.93 in 2013[23]. - The net profit attributable to shareholders in 2014 was CNY 5,956,603.04, a significant turnaround from a loss of CNY 70,713,027.60 in 2013, marking an increase of 108.42%[23]. - The net cash flow from operating activities improved to CNY 20,089,635.26 in 2014, a 205.65% increase from a negative cash flow of CNY 19,015,164.86 in 2013[23]. - Basic earnings per share for 2014 were CNY 0.0058, compared to a loss of CNY 0.0687 per share in 2013, reflecting an increase of 108.44%[23]. - The company reported a net profit excluding non-recurring gains and losses of CNY 266,351.56 in 2014, a significant improvement from a loss of CNY 73,782,349.92 in 2013, marking a 100.36% increase[23]. - The company reported a net loss of CNY 412,541,527.08 for the year, slightly improved from a loss of CNY 418,498,130.12 in the previous year[171]. - The company reported a net profit of CNY -9,186,246.14, an improvement from a net loss of CNY -99,464,723.89 in the previous period[178]. - The total comprehensive income for the year was -36,117,752.71 CNY, compared to -120,189,270.65 CNY in the previous year, reflecting a reduction in losses[183]. Assets and Liabilities - The total assets at the end of 2014 were CNY 818,082,450.17, a slight decrease of 0.55% from CNY 822,583,877.99 at the end of 2013[23]. - The company's total assets at the end of 2014 were CNY 817.56 million, with a significant portion allocated to fixed assets and ongoing construction projects[45]. - The total liabilities increased to CNY 96,490,512.25 from CNY 91,805,939.43, reflecting a rise of approximately 7.4%[170]. - The total liabilities decreased from CNY 98,939,892.21 to CNY 75,159,115.65, a reduction of approximately 24%[175]. - The company has no short-term borrowings or long-term borrowings as of the end of 2014, indicating a debt-free status[170]. Shareholder Information - The total number of shares is 1,029,556,222, with no changes during the reporting period[107]. - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 3.89% of the shares, with 40 million shares pledged[110]. - The company does not have a controlling shareholder or actual controller, with no single shareholder holding more than 30% of the shares[113]. - The company’s shareholding structure is relatively dispersed, preventing any single shareholder from having substantial influence over company decisions[114]. - The company has a total of 19,630,000 shares repurchased, accounting for 1.9% of the total share capital[112]. Operational Highlights - In 2014, Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. achieved a main business revenue of CNY 234,674,481.90, representing a year-on-year growth of 15.11%[30]. - The main business cost for the same period was CNY 97,396,814.60, which decreased by 5.59% compared to the previous year[34]. - The company reported total operating income of CNY 241,230,724.74, with main business income accounting for 97.28% of total revenue[31]. - The gross profit margin for the pharmaceutical segment was 58.50%, an increase of 9.10% compared to the previous year[41]. - The revenue from EPO products was CNY 73.91 million, with a gross margin of 69.43%, showing a year-on-year growth of 66.89%[41]. Cash Flow and Investments - Cash flow from operating activities showed a net inflow of CNY 20,089,635.26, a turnaround from a net outflow in the previous year[39]. - The company’s cash and cash equivalents decreased by CNY 111,944,300.17, indicating a decline of 98.58% year-on-year[40]. - Investment cash inflow increased by 119.47% year-on-year due to the recovery of entrusted loans[40]. - Cash flow from investment activities resulted in a net outflow of -123,678,438.00 CNY, worsening from -61,459,300.13 CNY in the previous year, indicating increased investment expenditures[186]. Corporate Governance and Compliance - The company has established a comprehensive corporate governance structure, ensuring clear responsibilities and compliance with regulatory requirements[138]. - The company has not experienced any insider trading incidents during the reporting period, maintaining compliance with insider information regulations[140]. - The company has not engaged in any related party transactions during the reporting period[86][88]. - The company received a standard unqualified audit opinion from the auditing firm for the financial statements[162]. Future Outlook and Strategy - The company anticipates significant market growth in the pharmaceutical industry driven by increasing healthcare awareness and an aging population, with a focus on expanding into rural markets[64]. - The company plans to enhance market sales efforts, improve production quality management, and increase the development of new health products in 2015[66]. - The company plans to focus on expanding its market presence and developing new products in the upcoming fiscal year[167].

江苏四环生物股份有限公司 2014 年第三季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2014-41 号 江苏四环生物股份有限公司 2014 年第三季度报告正文 1 江苏四环生物股份有限公司 2014 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 董事史兆俊无法保证 2014 年第三季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述 或重大遗漏,理由是：对新疆爱迪新能源科技有限公司的经营决策和设备采购合同有异议。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人徐殷及会计机构负责人(会计主管人员)徐殷声明：保证季度 报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2014 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报 ...

Financial Performance - The company achieved operating revenue of CNY 131,805,467.14, representing a year-on-year increase of 22.53%[21]. - The net profit attributable to shareholders reached CNY 22,866,490.75, a significant turnaround from a loss of CNY 1,181,422.06 in the same period last year, marking a growth of 2,035.51%[21]. - The net profit after deducting non-recurring gains and losses was CNY 19,952,947.33, up 865.95% compared to CNY 2,065,629.07 in the previous year[21]. - The company's basic and diluted earnings per share were both CNY 0.0222, a substantial increase of 2,118.18% from a loss of CNY 0.0011 per share last year[21]. - The weighted average return on net assets improved to 3.33%, compared to -0.16% in the previous year[21]. - The company's revenue for the reporting period was ¥131,805,467.14, representing a year-on-year increase of 22.53% compared to ¥107,572,043.03 in the same period last year[31]. - Operating profit amounted to CNY 26,668,075.80, significantly up from CNY 1,977,707.52 in the prior period[112]. - Net profit for the period was CNY 21,245,316.18, recovering from a net loss of CNY 3,947,568.04 in the same period last year[112]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 833,904,219.63, reflecting a 1.38% increase from CNY 822,583,877.99 at the end of the previous year[21]. - The net assets attributable to shareholders increased by 3.39% to CNY 697,977,238.69 from CNY 675,110,747.94 at the end of the previous year[21]. - Total liabilities decreased to CNY 81,880,964.89 from CNY 91,805,939.43, a decline of approximately 10.8%[106]. - Shareholders' equity increased to CNY 752,023,254.74 from CNY 730,777,938.56, reflecting a growth of about 2.9%[106]. - Current assets totaled CNY 444,340,918.16, slightly down from CNY 449,558,189.10, indicating a decrease of about 1.5%[104]. - Non-current assets rose to CNY 389,563,301.47 from CNY 373,025,688.89, representing an increase of approximately 4.4%[105]. Cash Flow - Cash flow from operating activities decreased by 71.05% to ¥7,481,507.63, down from ¥25,843,273.55 year-on-year[31]. - The net cash flow from investing activities improved by 74.71%, with a net outflow of ¥23,045,519.67 compared to ¥91,123,276.97 in the previous year[32]. - The cash outflow from investment activities was 116,455,480.80 RMB, with a net cash flow from investment activities of -23,045,519.67 RMB[119]. - The total cash inflow from operating activities was 4,814,969.61 RMB, significantly lower than 42,715,831.78 RMB in the previous period[122]. - The net increase in cash and cash equivalents was -18,962,952.50 RMB, reflecting a challenging cash flow environment[119]. Expenses - Operating costs increased to ¥54,842,749.19, a rise of 4.20% from ¥52,631,538.28 in the previous year[31]. - Sales expenses surged by 42.57% to ¥16,050,901.04, primarily due to increased promotional and hospitality expenses in Beijing[31]. - Management expenses decreased by 15.55% to ¥33,167,971.67, down from ¥39,276,330.61 year-on-year[31]. - The company reported a significant increase in income tax expenses, which rose by 102.51% to ¥5,424,148.89, attributed to higher profits from Beijing Sihuan[31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 167,315[90]. - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 40,000,000 shares, accounting for 3.89% of the total shares[91]. - Jiangyin Deyuan Wool Textile Co., Ltd. conducted a repurchase transaction of 19,630,000 shares, representing 1.91% of the total share capital[92]. - The total number of shares after the recent changes is 1,029,556,222, with 100% being unrestricted shares[88]. - There were no changes in the controlling shareholder or actual controller during the reporting period[93]. Business Strategy and Operations - The company plans to focus on expanding its market share and diversifying its business strategy in the health industry[29]. - The significant increase in revenue from the wholly-owned subsidiary Beijing Sihuan was attributed to increased supply following last year's GMP renovation[29]. - The company operates in the pharmaceutical industry, focusing on the production of injectables and other medications[136]. - The company has been listed on the Shenzhen Stock Exchange since 1993, under the stock code "000518" and the name "Sihuan Bio"[134]. Legal and Compliance - A lawsuit was filed against Xinjiang Aidi for 6 million yuan in construction payments, with the court date yet to be determined[84]. - The company has not engaged in any related party transactions during the reporting period[65][66]. - The company did not distribute cash dividends, issue bonus shares, or increase share capital from capital reserves in the previous year[51]. Research and Development - Research and development investment increased by 6.06% to ¥2,278,412.63, compared to ¥2,148,142.57 in the previous year[31]. - The company has not disclosed any new product developments or market expansion strategies in this report[107]. - The company has not reported any new product launches or technological advancements during this period[112]. Accounting Policies - The financial statements prepared by the company comply with the requirements of the enterprise accounting standards, reflecting a true and complete financial status[139]. - The company recognizes the fair value of identifiable net assets acquired in business combinations, with adjustments made to the current profit and loss if the fair value can be reliably measured[144]. - The company does not adjust the beginning balances of the consolidated balance sheet for subsidiaries acquired through non-same control business combinations[148].

江苏四环生物股份有限公司 2014 年第一季度报告正文 证券代码：000518 证券简称：四环生物 公告编号：临-2014-21 号 江苏四环生物股份有限公司 2014 年第一季度报告正文 1 江苏四环生物股份有限公司 2014 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐殷声明：保证季度报告中财务报表的真实、准确、完整。 2 江苏四环生物股份有限公司 2014 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 74,755,076.02 | 51,263,649.93 ...

江苏四环生物股份有限公司 2013 年度报告全文 江苏四环生物股份有限公司 2013 年度报告 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人孙国建、主管会计工作负责人及会计机构负责人(会计主管人员) 徐殷声明：保证年度报告中财务报告的真实、准确、完整。 2 | 目录 | | --- | | 年度报告 2 2013 | | --- | | 一、重要提示、目录和释义 2 | | 二、公司简介 6 | | 三、会计数据和财务指标摘要 8 | | 四、董事会报告 10 | | 五、重要事项 20 | | 六、股份变动及股东情况 25 | | 七、董事、监事、高级管理人员和员工情况 28 | | 八、公司治理 34 | | 九、内部控制 38 | | 十、财务报告 40 | | 十一、备查文件目录 113 | 2014 年 04 月 1 江苏四环生物股份有限公司 2013 ...